Badyket may be available in the countries listed below.
Bemiparin Sodium is reported as an ingredient of Badyket in the following countries:
International Drug Name Search
Diclonatrium may be available in the countries listed below.
Diclofenac sodium salt (a derivative of Diclofenac) is reported as an ingredient of Diclonatrium in the following countries:
International Drug Name Search
Inotrin may be available in the countries listed below.
Isotretinoin is reported as an ingredient of Inotrin in the following countries:
International Drug Name Search
Tanlozid may be available in the countries listed below.
Hydrochlorothiazide is reported as an ingredient of Tanlozid in the following countries:
Losartan potassium salt (a derivative of Losartan) is reported as an ingredient of Tanlozid in the following countries:
International Drug Name Search
Glemid may be available in the countries listed below.
Glimepiride is reported as an ingredient of Glemid in the following countries:
International Drug Name Search
Dompéridone Mylan may be available in the countries listed below.
Domperidone is reported as an ingredient of Dompéridone Mylan in the following countries:
International Drug Name Search
Tetracosactide Acetate may be available in the countries listed below.
Tetracosactide Acetate (BANM) is also known as Tetracosactide (Rec.INN)
International Drug Name Search
Glossary
| BANM | British Approved Name (Modified) |
| Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
Generic Name: liothyronine (LYE oh THYE roe neen)
Brand names: Cytomel, Triostat
Liothyronine is a man-made form of a hormone that is normally produced by your thyroid gland to regulate the body's energy and metabolism. Liothyronine is given when the thyroid does not produce enough of this hormone on its own.
Liothyronine treats hypothyroidism (low thyroid hormone). Liothyronine is also used to treat or prevent goiter (enlarged thyroid gland), and is also given as part of a medical tests for thyroid disorders.
Liothyronine should not be used to treat obesity or weight problems.
Liothyronine may also be used for purposes not listed in this medication guide.
Before taking liothyronine, tell your doctor if you have heart disease, angina (chest pain), coronary artery disease, congestive heart failure, diabetes, or problems with your pituitary or adrenal glands.
To be sure this medication is helping your condition, your blood may need to be tested often. Visit your doctor regularly.
Keep using this medicine as directed, even if you feel well. You may need to take thyroid medication for the rest of your life.
To make sure you can safely take liothyronine, tell your doctor if you have any of these other conditions:
heart disease, angina (chest pain);
coronary artery disease;
congestive heart failure;
any type of diabetes; or
problems with your pituitary or adrenal gland.
Take exactly as prescribed by your doctor. Do not take in larger or smaller amounts or for longer than recommended. Follow the directions on your prescription label.
Liothyronine is usually taken once daily. Follow your doctor's instructions.
Your doctor may occasionally change your dose to make sure you get the best results.
If you are switching to liothyronine from any other thyroid medication, stop using the other medication before you start taking liothyronine.
To be sure this medication is helping your condition, your blood may need to be tested often. Visit your doctor regularly.
Keep using this medicine as directed, even if you feel well. You may need to take thyroid medication for the rest of your life.
See also: Liothyronine dosage (in more detail)
Take the missed dose as soon as you remember. Skip the missed dose if it is almost time for your next scheduled dose. Do not take extra medicine to make up the missed dose.
Overdose symptoms may include headache, sweating, diarrhea, irregular menstrual periods, confusion, weakness, swelling in your hands or feet, fast heart rate, chest pain, feeling short of breath, fainting, or feeling nervous, restless, or irritable.
If you also take cholestyramine (Prevalite, Questran) or colestipol (Colestid), avoid taking these medications within 4 hours before or after you take liothyronine.
Less serious side effects may include temporary hair loss (especially in children).
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Usual Adult Dose for Hypothyroidism:
Initial dose: 25 mcg orally once a day; may be increased by up to 25 mcg every 1 to 2 weeks depending on the patient's clinical response and laboratory findings
Maintenance dose: 25 to 75 mcg daily
Usual Adult Dose for Myxedema:
Initial dose: 5 mcg orally once a day; may be increased by 5 to 10 mcg every 1 to 2 weeks depending on the patient's clinical response and laboratory findings
When treatment is up to 25 mcg/day, the dosage may be increased by 5 to 25 mcg every week or two until a satisfactory therapeutic response is attained.
Maintenance dose: 50 to 100 mcg daily
Usual Adult Dose for Myxedema Coma:
25 to 50 mcg intravenously
If the patient has known or suspected cardiovascular disease, then an initial dose of 10 to 20 mcg in conjunction with cardiac monitoring is recommended.
Subsequent doses should be determined by the patient's clinical condition and response to treatment. Generally, doses should be administered at least 4 hours and no more than 12 hours apart. Caution is advised in adjusting the dose due to the potential of acute and large changes to precipitate adverse cardiovascular events.
Available clinical data indicate reduced mortality in patients receiving at least 65 mcg/day in the initial days of treatment. However, there is limited clinical experience with dosages above 100 mcg/day.
Oral thyroid hormone therapy should be substituted as soon as the patient is stable and able to take oral medication. If levothyroxine rather than liothyronine is used, the prescriber should bear in mind that there is a delay of several days in the onset of levothyroxine activity and that intravenous therapy should be discontinued gradually.
Usual Adult Dose for Thyroid Suppression Test:
75 to 100 mcg orally once a day for 7 days
Radioactive (131) iodine uptake should be determined before and after the administration of thyroid hormone. If thyroid function is under normal control, the radioactive iodine uptake should drop significantly after treatment. A 50% or greater suppression of uptake indicates a normal thyroid-pituitary axis and rules out thyroid gland autonomy.
Liothyronine should be administered cautiously if there is a strong suspicion of thyroid gland autonomy, as exogenous hormone effects will be additive to those of the endogenous source.
Usual Adult Dose for TSH Suppression:
Initial dose: 5 mcg orally once a day; may be increased by 5 to 10 mcg every 1 to 2 weeks depending on the patient's clinical response and laboratory findings
When treatment is up to 25 mcg/day, the dosage may be increased by 12.5 to 25 mcg every week or two until a satisfactory therapeutic response is attained.
Maintenance dose: 75 mcg daily
Usual Pediatric Dose for Hypothyroidism:
Congenital hypothyroidism/Hypothyroidism:
Infants and Children less than or equal to 3 years:
Initial dose: 5 mcg orally once a day; may be increased by 5 mcg every 3 days to a maximum dosage of 20 mcg/day for infants and 50 mcg/day for children 1 to 3 years of age.
Hypothyroidism:
Initial dose: Children: 5 mcg orally once a day. Increase in 5 mcg/day increments every 3 to 4 days
Usual maintenance dose:
Infants: 20 mcg orally once a day
Children 1 to 3 years: 50 mcg orally once a day
Children greater than 3 years: Full adult dosage may be necessary
Goiter (nontoxic):
Children:
Initial dose: 5 mcg orally once a day. Increase in 5 mcg/day increments every 1 to 2 weeks
Maintenance dose: 15 to 20 mcg orally once a day
Goiter (nontoxic):
Children: 5 mcg orally once a day. Increase in 5 mcg/day increments every 1 to 2 weeks
Maintenance dose 15 to 20 mcg orally once a day
Tell your doctor about all other medicines you use, especially:
birth control pills or hormone replacement therapy;
a blood thinner such as warfarin (Coumadin);
digoxin (digitalis, Lanoxin);
epinephrine (EpiPen) or norepinephrine (Levophed);
insulin or oral diabetes medication;
medications that contain iodine (such as I-131);
an antidepressant such as amitriptyline (Elavil, Vanatrip), doxepin (Sinequan), desipramine (Norpramin), imipramine (Janimine, Tofranil), nortriptyline (Pamelor), and others;
salicylates such as aspirin, Backache Relief Extra Strength, Novasal, Nuprin Backache Caplet, Doan's Pills Extra Strength, Pepto-Bismol, Tricosal, and others;
steroids such as prednisone and others.
This list is not complete and other drugs may interact with liothyronine. Tell your doctor about all medications you use. This includes prescription, over-the-counter, vitamin, and herbal products. Do not start a new medication without telling your doctor.
See also: liothyronine side effects (in more detail)
Dicofan may be available in the countries listed below.
Sodium Phosphate (32P) is reported as an ingredient of Dicofan in the following countries:
International Drug Name Search
Vomisin may be available in the countries listed below.
Dimenhydrinate is reported as an ingredient of Vomisin in the following countries:
International Drug Name Search
Alerviden may be available in the countries listed below.
Cetirizine dihydrochloride (a derivative of Cetirizine) is reported as an ingredient of Alerviden in the following countries:
International Drug Name Search
Diabamyl may be available in the countries listed below.
Metformin hydrochloride (a derivative of Metformin) is reported as an ingredient of Diabamyl in the following countries:
International Drug Name Search
Dimethisoquin may be available in the countries listed below.
Dimethisoquin (BAN) is also known as Quinisocaine (Rec.INN)
International Drug Name Search
Glossary
| BAN | British Approved Name |
| Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
This product is intended for use only by physicians who are experienced in the use of allergenic extracts, or for use under the guidance of an allergist.
Allergenic extracts may potentially elicit a severe life-threatening systemic reaction, rarely resulting in death.7 Therefore, emergency measures and personnel trained in their use should be available immediately in the event of such a reaction. Patients should be instructed to recognize adverse reaction symptoms and cautioned to contact the physician's office if symptoms occur.
Scratch, prick or puncture test first. Test intradermally only to those antigens giving negative or questionable reactions on scratch, prick or puncture testing.
This product should never be injected intravenously.
Patients on non-selective beta blockers may be more reactive to allergens given for testing or treatment and may be unresponsive to the usual doses of epinephrine used to treat allergic reactions.6
Refer also to the WARNINGS, PRECAUTIONS, and ADVERSE REACTIONS Sections below for further discussion.
Allergenic extracts for intradermal testing used according to the DOSAGE AND ADMINISTRATION Section, produce erythema or erythema and wheal reactions in patients with significant IgE-mediated sensitivity to the relevant allergen. This allergic inflammatory response, although not completely understood, is thought to begin with the reaction of antigen with IgE on the surface of basophils, or mast cells, which initiates a series of biochemical events resulting in the production of histamine, slow-reacting substance of anaphylaxis and other mediators. These, in turn, produce the immediate-type wheal and flare skin reaction.
Certain diagnostics carry labeling which states Allergenic Extract for Diagnostic Use Only. Data to support the therapeutic use of products labeled with this statement have not been established.15
In addition to a carefully taken history, the use of intradermal testing extracts is an accepted method in the diagnosis of allergenic conditions.1, 2, 3 When scratch, prick or puncture reactions are small, or if the patient gives a history of allergic symptoms to a substance but scratch, prick or puncture tests are inconclusive, intradermal tests may be indicated. However, ANTIGENS PRODUCING LARGE 3 TO 4+ SCRATCH, PRICK OR PUNCTURE TESTS SHOULD NOT BE TESTED INTRADERMALLY.
Extracts of all allergens do not produce equivalent results in intradermal testing. The intensity of the skin reaction produced will be determined by two factors: the degree of sensitivity of the patient and the nature of the antigenic extract applied. In general, pollen extracts produce whealing reactions, whereas other inhalants produce erythematous reactions with wheals less often. Skin tests to foods seldom produce whealing reactions except for infrequent instances of severe sensitivity to fish, nuts or spices, and rarely other foods.
There are no known absolute contraindications to allergy skin testing. Patients with cardiovascular diseases or pulmonary diseases such as symptomatic asthma, and/or who are receiving cardiovascular drugs such as beta blockers, may be at higher risk for severe adverse reactions. These patients may also be more refractory to the normal anaphylaxis treatment regime.
Scratch, prick or puncture test first. Test intradermally only to those antigens giving negative or questionable reactions on scratch, prick or puncture testing. Excessively large local reactions or systemic reactions are more likely to occur if the patient is skin tested shortly after exposure to large amounts of antigen to which he or she is sensitive. Therefore, use caution when applying pollen tests to patients during their active pollen season, or after an exposure to inhalant allergens that produce symptoms. Refer to boxed WARNINGS Section.
Patients should be instructed in the recognition of adverse reactions to diagnostic testing. Patients should be made to understand the importance of a 30 to 45 minute observation period and be warned to return to the office promptly if symptoms occur after leaving.
Long-term studies in animals have not been conducted with allergenic extracts to determine their potential for carcinogenicity, mutagenicity or impairment of fertility.
4,5 Pregnancy Category C. Animal reproduction studies have not been conducted with allergenic extracts. It is also not known whether allergenic extracts can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Allergenic extracts should be given to a pregnant woman only if clearly needed.
There are no current studies on secretion of the allergenic extract components in human milk or effect on the nursing infant. Because many drugs are excreted in human milk, caution should be exercised when allergenic extracts are administered to a nursing woman.
Patients on non-selective beta blockers may be more reactive to allergens given for testing or treatment and may be unresponsive to the usual doses of epinephrine used to treat allergic reactions.6
Certain medications may lessen the skin test wheal and erythema responses elicited by allergens and histamine for varying time periods. Conventional antihistamines should be discontinued at least 5 days before skin testing. Long acting antihistamines should be discontinued for at least 3 weeks prior to skin testing.10Topical steroids should be discontinued at the skin test site for at least 2-3 weeks before skin testing. 10, 11 Tricyclic antidepressants such as Doxepin should be withheld for at least 7 days before skin testing.12Topical local anesthetics may suppress the flare responses and should be avoided in skin test sites. 13
Skin test wheal size decreases with age. The decrease in allergeninduced skin test reaction parallels that to histamine; therefore, appropriate positive skin test controls should always be performed.1
Wheal sizes in response to allergen skin testing can be smaller in infants than in adults. The skin response to histamine parallels that for allergens; therefore, appropriate postitive control skin tests should always be performed.1
1. Local Reactions
Large, persistent local reactions or minor exacerbations of the patient's allergic symptoms may be treated by local cold applications and/or the use of oral antihistamines, but they should be considered a warning of possible severe systemic reactions.
2. Systemic Reactions
With careful attention to dosage and administration, such reactions occur infrequently, but it must be remembered that allergenic extracts are highly potent in sensitive individuals and OVERDOSE could result in anaphylactic symptoms. Therefore, it is imperative that physicians administering allergenic extracts understand and be prepared for the treatment of severe reactions. Adverse reaction frequency data for allergenic extract administration for testing and treatment show that risk is low.7, 8 It cannot be overemphasized that, under certain unpredictable combinations of circumstances, anaphylactic shock is a possibility. Other possible systemic reaction symptoms, in varying degrees of severity, are fainting, pallor, bradycardia, hypotension, angioedema, cough, wheezing, conjunctivitis, rhinitis and urticaria. If a systemic or anaphylactic reaction does occur, apply a tourniquet above the site of injection, if tests are performed on the arms, and inject the 1:1000 epinephrine-hydrochloride intramuscularly or subcutaneously into the opposite arm. Loosen the tourniquet at least every 10 minutes. Do not obstruct arterial blood flow with the tourniquet.
| AU/mL that Elicited ∑E = 50 mm | |||
|---|---|---|---|
| Allergen | Number of Persons | Mean | 2 Std. Dev. Range |
| D. farinae | 12 | 0.0609 | 0.0015-2.6016 |
| D. pteronyssinus | 12 | 0.333 | 0.0003-4.0077 |
The dose is the same in patients of all age groups. Because the wheal size in response to allergen skin testing decreases with age, appropriate histamine positive control skin tests must be performed.1
The dose is the same in patients of all age groups. Wheal size in response to allergen skin testing can be smaller in infants than in adults. Appropriate histamine positive control skin tests must be performed.1
Refer to the following table to determine the skin test sensitivity grade. The corresponding ∑E (sum of the longest diameter and the mid-point orthogonal diameters of erythema) is also presented.
| Grade | Erythema mm | Papule or Wheal mm | Coresponding mm ∑E |
|---|---|---|---|
| 0 | <5 | <5 | <10 |
| ± | 5-10 | 5-10 | 10-20 |
| 1+ | 11-20 | 5-10 | 20-40 |
| 2+ | 21-30 | 5-10 | 40-60 |
| 3+ | 31-40 | 10-15 (a) | 60-80 |
| 4+ | >40 | >15 (b) | > 80 |
a or with pseudopods
b or with many pseudopods
A positive skin reaction to any allergen must be interpreted in light of the patient’s history of symptoms, time of year, known exposures, and eating habits.
THE SKIN TESTS ARE IN NO WAY A SUBSTITUTE FOR A CAREFUL ALLERGENIC HISTORY; RATHER, THEY SERVE AS ADDITIONAL INFORMATION TO AID IN IDENTIFYING CAUSATIVE ALLERGENS IN PATIENTS WITH ALLERGIC DISORDERS.
Most allergens are available in multiple dose 5 mL vials at PNU, w/v, some mixes as Concentrate, Standardized Mite products at AU/mL (30 AU/mL and 300 AU/mL each species), or Standardized Grass products at BAU/mL [100 BAU/mL and 1,000 BAU/mL (Bermuda 100 BAU/mL only)]. Product labels state vials are for intradermal testing and list strengths.
A number of factors beyond our control could reduce the efficacy of this product or even result in an ill effect following its use. These include storage and handling of the product after it leaves our hands, diagnosis, dosage, method of administration and biological differences in individual patients. Because of these factors, it is important that this product be stored properly, and that the directions be followed carefully during use. No warranty, express or implied, including any warranty of merchantability or fitness, is made. Representatives of the Company are not authorized to vary the terms or the contents of any printed labeling, including the package insert, for this product except by printed notice from the Company’s headquarters. The prescriber and user of this product must accept the terms hereof.
| ANIMAL ALLERGENS, AP HORSE HAIR AND DANDER ap horse hair and dander injection, solution | ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| Marketing Information | |||
| Marketing Category | Application Number or Monograph Citation | Marketing Start Date | Marketing End Date |
| BLA | BLA103888 | 01/30/1978 | |
| ANIMAL ALLERGENS, AP CATTLE HAIR AND DANDER cattle hair and dander injection, solution | ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| Marketing Information | |||
| Marketing Category | Application Number or Monograph Citation | Marketing Start Date | Marketing End Date |
| BLA | BLA103888 | 01/30/1978 | |
| ANIMAL ALLERGENS, FEATHER MIX feather mix injection, solution | ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| Marketing Information | |||
| Marketing Category | Application Number or Monograph Citation | Marketing Start Date | Marketing End Date |
| BLA | BLA103888 | 04/19/1941 | |
| AP HOUSE DUST MIX ap house dust mix injection, solution | ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| Marketing Information | |||
| Marketing Category | Application Number or Monograph Citation | Marketing Start Date | Marketing End Date |
| BLA | BLA103888 | 08/17/1972 | |
| DUST, HOUSE MIXTURE dust, house mixture injection, solution | ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| Marketing Information | |||
| Marketing Category | Application Number or Monograph Citation | Marketing Start Date | Marketing End Date |
| BLA | BLA103888 | 04/19/1941 | |
| INSECTS (WHOLE BODY) COCKROACH MIX insects (whole body) cockroach mix injection, solution | |||||||
| |||||||
Generic Name: acetaminophen and diphenhydramine (a SEET a MIN oh fen and DYE fen HYE dra meen)
Brand Names: Anacin P.M. Aspirin Free, Coricidin Night Time Cold Relief, Excedrin PM, Excedrin PM Caplet, Excedrin PM Express Gels, Headache Relief PM, Legatrin PM, Mapap PM, Midol PM, Night Time Pain, Percogesic Extra Strength, Percogesic Original Strength, Tylenol Cold Relief Caplet, Tylenol Cold Relief Nighttime, Tylenol Cold Relief Nighttime Caplet, Tylenol Extra Strength PM, Tylenol Extra Strength PM Rapid Release Gelcaps, Tylenol Extra Strength PM Vanilla Caplet, Tylenol PM, Tylenol Sore Throat Nighttime, Unisom with Pain Relief
Acetaminophen is a pain reliever and fever reducer.
Diphenhydramine is an antihistamine that reduces the natural chemical histamine in the body. Histamine can produce symptoms of sneezing, itching, watery eyes, and runny nose.
The combination of acetaminophen and diphenhydramine is used to treat headache, fever, body aches, runny or stuffy nose, sneezing, itching, watery eyes, and sinus congestion caused by allergies, the common cold, or the flu.
Acetaminophen and diphenhydramine may also be used for purposes not listed in this medication guide.
Ask a doctor or pharmacist if it is safe for you to take this medicine if you have:
liver disease, cirrhosis, or a history of alcoholism;
a blockage in your digestive tract (stomach or intestines);
kidney disease;
cough with mucus, or cough caused by smoking, emphysema, or chronic bronchitis;
enlarged prostate or urination problems;
low blood pressure; or
if you take potassium (Cytra, Epiklor, K-Lyte, K-Phos, Kaon, Klor-Con, Polycitra, Urocit-K).
Use exactly as directed on the label, or as prescribed by your doctor. Do not use in larger or smaller amounts or for longer than recommended. This medicine is usually taken only for a short time until your symptoms clear up.
Measure liquid medicine with a special dose-measuring spoon or medicine cup, not with a regular table spoon. If you do not have a dose-measuring device, ask your pharmacist for one.
Do not take for longer than 7 days in a row. Stop taking the medicine and call your doctor if you still have a fever after 3 days of use, you still have pain after 7 days (or 5 days if treating a child), if your symptoms get worse, or if you have a skin rash, ongoing headache, or any redness or swelling.
Since this medicine is taken when needed, you may not be on a dosing schedule. If you are taking the medication regularly, take the missed dose as soon as you remember. Skip the missed dose if it is almost time for your next scheduled dose. Do not take extra medicine to make up the missed dose.
The first signs of an acetaminophen overdose include loss of appetite, nausea, vomiting, stomach pain, sweating, and confusion or weakness. Later symptoms may include pain in your upper stomach, dark urine, and yellowing of your skin or the whites of your eyes.
Overdose symptoms may also include severe forms of some of the side effects listed in this medication guide.
chest pain, rapid pulse, fast or uneven heart rate;
confusion, hallucinations, severe nervousness;
tremor, seizure (convulsions);
easy bruising or bleeding, unusual weakness;
urinating less than usual or not at all; or
nausea, pain in your upper stomach, itching, loss of appetite, dark urine, clay-colored stools, jaundice (yellowing of your skin or eyes).
Less serious side effects may include:
dizziness, drowsiness;
mild headache;
dry mouth, nose, or throat;
constipation;
blurred vision;
feeling nervous; or
sleep problems (insomnia);
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Tell your doctor about all other medicines you use, especially:
leflunomide (Arava);
topiramate (Topamax);
zonisamide (Zonegran);
diphenhydramine (Benadryl) applied to the skin;
an antibiotic, antifungal medicine, sulfa drug, or tuberculosis medicine;
an antidepressant;
birth control pills or hormone replacement therapy;
bladder or urinary medications;
blood pressure medication;
a bronchodilator;
cancer medicine;
cholesterol-lowering medications such as Lipitor, Niaspan, Zocor, Vytorin, and others;
gout or arthritis medications (including gold injections);
HIV/AIDS medication;
medication for nausea and vomiting, stomach ulcers, or irritable bowel syndrome;
medicines to treat psychiatric disorders;
an NSAID such as Advil, Aleve, Arthrotec, Cataflam, Celebrex, Indocin, Motrin, Naprosyn, Treximet, Voltaren, others; or
seizure medication.
This list is not complete and other drugs may interact with acetaminophen and diphenhydramine. Tell your doctor about all medications you use. This includes prescription, over-the-counter, vitamin, and herbal products. Do not start a new medication without telling your doctor.
See also: Tylenol Cold Relief Nighttime Caplet side effects (in more detail)
Rec.INN
A06AB08
0010040-45-6
C18-H13-N-Na2-O8-S2
481
Laxative, antiresorptive and/or secretagogue
Stimulant laxative
Phenol, 4,4'-(2-pyridinylmethylene)bis-, bis(hydrogen sulfate) (ester), disodium salt
International Drug Name Search
Glossary
| BAN | British Approved Name |
| DCF | Dénomination Commune Française |
| DCIT | Denominazione Comune Italiana |
| IS | Inofficial Synonym |
| JAN | Japanese Accepted Name |
| OS | Official Synonym |
| PH | Pharmacopoeia Name |
| Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
Di-Fedril may be available in the countries listed below.
Diphenhydramine hydrochloride (a derivative of Diphenhydramine) is reported as an ingredient of Di-Fedril in the following countries:
International Drug Name Search
